HOME ·

02005.HK

SSY Group (02005.HK) Secures Production Approval for Four Drugs; Second Domestic Firm to Launch Emedastine Difumarate Eye Drops
Tags：
SSY Group02005.HKdrug production registration approval
2026-05-21
SSY Group (02005.HK): Obtains Production Registration Approvals for Three Products; Fat-Soluble Vitamin Injection Approved as First Domestic Enterprise
Tags：
SSY Group02005.HKConsistencyEvaluation
2026-05-06
SSY Group (02005.HK): Diltiazem Hydrochloride for Injection and Propranolol Hydrochloride Injection Obtain Drug Production Registration Approvals
Tags：
SSY Group02005.HKdrug production registration approval
2026-04-27
SSY GROUP (02005.HK): Calcium Chloride API Approved for Registration by NMPA
Tags：
SSY Group02005.HKPharmaceuticalAPI
2026-03-19
SSY GROUP(02005.HK): Bumetanide API Approved by NMPA
Tags：
SSY Group02005.HKAPI
2026-03-16
SSY Group Limited (02005.HK): Calcium Levofolinate for Injection Approved, Deemed to Have Passed Consistency Evaluation
Tags：
SSY Group02005.HKdrug production registration approval
2026-03-06
SSY Group Limited (02005.HK): Obtains Drug Production Registration Approval for Doxapram Hydrochloride Injection, First Approved in China
Tags：
SSY Group02005.HKnew drug launch
2026-03-03
SSY Group(02005.HK): Two APIs Approved by NMPA for Marketing
Tags：
SSY Group02005.HKAPI
2026-02-27
SSY Group (02005.HK): Secures Production Registration Approval for New 2ml Specification of Potassium Dihydrogen Phosphate Complex Injection
Tags：
SSY Group02005.HKdrug production registration approval
2026-01-26
SSY Group (02005.HK): Sodium Glycerophosphate Injection Obtains NMPA Drug Production Registration Approval
Tags：
SSY Group02005.HKNew Drug Update
2025-12-30